Displaying drugs 6326 - 6350 of 6893 in total
Buflomedil
Experimental
Oxiracetam
Experimental
(6S)-5,6,7,8-tetrahydrofolic acid
Experimental
RU90395
Experimental
6-hydroxy-FAD
Experimental
GDP-alpha-D-mannuronic acid
Experimental
Cpad
Experimental
Histidyl-Adenosine Monophosphate
Experimental
Adenylosuccinic acid
Experimental
Vapreotide
Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.
Experimental
Investigational
Matched Iupac: … (2R)-2-amino-N-[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-{[(1S)-1-carbamoyl-2-(1H-indol-3-yl)ethyl …
Temafloxacin
Temafloxacin is an antibiotic agent belonging to the fluoroquinolone drug class. It was first approved for use in the U.S. market in 1992, but was withdrawn shortly due to the reports of serious adverse reactions, such as allergic reactions and hemolyric anemia, resulting in three deaths.
Withdrawn
Alrestatin
Experimental
2-Chlorodideoxyadenosine
Experimental
Genz-10850
Experimental
Gavestinel
Highly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.
Investigational
Volixibat
Volixibat, also known as SHP626 or LUM002, is an investigational drug that will potentially be used for the treatment of Non-Alcoholic Steatohepatitis (NASH). If approved for use, it will be the first available agent for the treatment of NASH.
Volixibat is a selective inhibitor of the apical sodium-dependent bile acid...
Experimental
Investigational
Displaying drugs 6326 - 6350 of 6893 in total